Peter Kabos, MD

Balakrishnan I, Yang X, Brown J, Ramakrishnan A, Torok-Storb B, Kabos P, Hesselberth JR, Pillai MM. Genome-Wide Analysis of miRNA-mRNA Interactions in Marrow Stromal Cells. Stem Cells. 2014 Mar;32(3):662-73. PubMed PMID: 24038734

Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer. 2013 Feb;4(1):36-49. PubMed PMID: 23184698

Elias A, Bowles D, Kabos P: Adjuvant Systemic Therapy. Early Diagnosis of Cancer Series: Breast Cancer. Lisa Jacobs and Christina Finlayson (Ed). Elsevier. (In press)

The Integration of Locoregional with Systemic Adjuvant Therapy for Early Stage Breast Cancer: the Shifting Sands of Decision Making Christine Fisher, Jennifer R. Diamond, Nicole Kounalakis, Peter Kabos, Jose Mayordomo, Rachel Rabinovitch, Christina Finlayson, Virginia F. Borges, Anthony D. Elias Breast Cancer Management, In Press

Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer. Kabos P, Borges VF.Expert Opin Pharmacother. 2010 Apr;11(5):807-16.

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab-—a translational project in the neoadjuvant GeparQuinto trial. Peter Kabos, Anthony Elias. Breast Diseases: A Year Book Quarterly.

Progestin Gene Regulation in Dual PR/AR Positive Breast Tumors. SAT-296 Endocrine Society 2013. Schultz JF, Hendricks P, Rosen R, Flory K, Elias A, Jabobsen B, Kabos P, Sartorius C.

Kabos P, Haughian J, Wang X, Dye W, Finlayson C, Elias A, Horwitz K, Sartorius C. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat, 2010 July 28

Genome-wide analysis of miRNA-mRNA interactions in breast cancer. Pillai MM, Gillen A, Yamamoto TM, Kline E, Brown J, Flory K, Hesselberth JR and Kabos P.

2. Kabos P, Borges V: Surveillance and Detection of Recurrence. Early Diagnosis of Cancer Series: Breast Cancer. Lisa Jacobs and Christina Finlayson (Ed). Elsevier

Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2014 Sep 22;0. [Epub ahead of print] PubMed PMID: 25241899

Pillai MM, Gillen AE, Yamamoto TM, Kline E, Brown J, Flory K, Hesselberth JR, Kabos P. HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer. Breast Cancer Res Treat. 2014 Jul;146(1):85-97. PubMed PMID: 24906430

Reid BG, Jerjian T, Patel P, Zhou Q, Yoo BH, Kabos P, Sartorius CA, Labarbera DV. Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery. Curr Chem Genomics Transl Med. 2014;8(Suppl 1):27-35. PubMed PMID: 24596682

3. Elias A, Bowles D, Kabos P: Adjuvant Systemic Therapy. Early Diagnosis of Cancer Series: Breast Cancer. Lisa Jacobs and Christina Finlayson (Ed). Elsevier.

Carlson JA, Nooruddin Z, Rusthoven C, Elias A, Borges VF, Diamond JR, Kavanagh B, Kabos P. Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema. Neuro Oncol. 2014 Jul;16(7):1006-9. PubMed PMID: 24497407

Balakrishnan I, Yang X, Brown J, Ramakrishnan A, Torok-Storb B, Kabos P, Hesselberth JR, Pillai MM. Genome-wide analysis of miRNA-mRNA interactions in marrow stromal cells. Stem Cells. 2014 Mar;32(3):662-73. PubMed PMID: 24038734

Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA. Breast Cancer Res Treat. 2011 Jul;128(1):45-55

Kabos P, Li C, Finlay-Schultz J, Kline E, Edgerton S, Wissel J, Finlayson C, Elias A, Sartorius C. A patient-derived tumor model to study hormone receptor action and luminal specific stem/progenitor cells in estrogen receptor positive breast cancer. AACR, San Francisco, October 2011

Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Elias A, Sartorius CA, and Kabos P. CD146 positive and negative stroma direct breast tumor estrogen receptor levels, therapeutic response and metastatic potential. 37th San Antonio Breast Cancer Symposia, December 2014.

Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA and LaBarbera DV. A high content assay to identify small molecule modulators of a cancer stem cell population in luminal breast cancer. J Mol Screening, 2012 Jun 29 [Epub ahead of print] PMID: 22751729

Iwanaga R, Wang CA, Micalizzi2 DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP and Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of ERK and TGF-ß signaling pathways. Breast Cancer Res, 2012 Jul 5;14(4):R100. PMID:22765220.

Cittelly DM, Cruz H, Serkova N, Borges V, Kabos P, Steeg PS, and Sartorius CA. Estrogen signaling through astrocytes promotes migration and invasion of ER-negative breast cancer cells. 37th San Antonio Breast Cancer Symposia, December 2014.

Fisher CM, Diamond JR, Kounalakis N, Kabos P, Mayordomo J, Rabinovitch RA, Murphy C, Finlayson C, Borges VF, Elias AD. The integration of locoregional with systemic adjuvant therapy for early-stage breast cancer: the shifting sands of decision-making. Breast Cancer Management. 2014; 3(2), 205-212.

Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Edgerton SM, Harrell JC, Elias A and Sartorius CA. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen dependent gene signatures. Breast Cancer Res Treat, 2012 DOI: 10.1007/s10549-012-2164-8.

Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer. 2013 Feb;4 (1):36-49

Kabos P, Kline E, Brown J, Flory K, Sartorius C, Hesselberth J, Pillai MM High throughput sequencing following cross-linked immuneprecipitation (HITS-CLIP) of Argonaute protein reveals novel miRNA regulatory pathways of estrogen receptor in breast cancer. San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2012

Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nat Commun. 2015 Dec 21;6:10077. PubMed PMID: 26687066

Sartorius CA, Finlay-Schultz J, Li C, Rosen RB, Hendricks P, Wisell J, Finlayson C, Elias A, Kabos P. Progestins exert divergent growth effects and regulate tumor-unique gene cohorts in patient derived breast cancer xenografts. San Antonio Breast Cancer Symposium, Texas, December 2012

Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, Kabos P, Schedin TB, Borges VF, Steeg PS, Cittelly DM. Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene. 2015 Sep 28. [Epub ahead of print] PubMed PMID: 26411365

Jasem J, Altoos B, Fisher CM, Elias AD, Kounalakis N, Borges VF, Kabos P. Multiple Hepatic Lesions in a Patient With a History of DCIS. Oncology (Williston Park). 2015 Sep;29(9):669-70, 678-9. PubMed PMID: 26384804

Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 May;14(5):1117-29. PubMed PMID: 25758253

Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2015 Jul;34(28):3676-87. PubMed PMID: 25241899

Finlay-Schultz J, Brechbuhl HM, Rosen RB, Gillen AE, Jacobsen BM, Kabos P, and Sartorius CA. Context dependent growth effects of progestins in estrogen receptor positive breast cancer patient-derived xenografts (PDX). American Association for Cancer Research, Advances in Breast Cancer Research, Bellvue, WA, October 2015, Poster.

Hanna C, Jacobsen BM, Sartorius CA, Kabos P, Lillehei K, Ormond DR, Graner M, Borges V, and Cittelly DM. Insights into brain metastases biology using novel brain-metastases-derived xenografts and cell lines. American Association for Cancer Research, Advances in Breast Cancer Research, Bellvue, WA, October 2015, Poster.

Wellberg E, Jacobsen BM, Kabos P, MacLean PS, and Sartorius CA. A patient-derived xenograft model to study the effect of postmenopausal obesity on endocrine resistance. American Association for Cancer Research, Advances in Breast Cancer Research, Bellvue, WA, October 2015, Poster.

Finlay-Schultz J, Brechbuhl HM, Jacobsen BM, Kabos P, and Sartorius CA. A prospective steroid receptor interactome that dictates progestin effects in ER+ breast cancers. Mammary Gland Biology Gordon Research Conference, West Dover, VT June 2015.

Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, Kabos P, Schedin TB, Borges VF, Steeg PS, Cittelly DM. Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene. 2016 Jun 2;35(22):2881-92. PubMed PMID: 26411365

Jasem J, Amini A, Rabinovitch R, Borges VF, Elias A, Fisher CM, Kabos P. 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile. J Clin Oncol. 2016 Jun 10;34(17):1995-2002. PubMed PMID: 27001563

Gillen AE, Yamamoto TM, Kline E, Hesselberth JR, Kabos P. Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts. BMC Genomics. 2016 May 5;17:338. PubMed PMID: 27150721

Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2016 Oct 4. [Epub ahead of print] PubMed PMID: 27702820

Schade H, Davis L, Kabos P. Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer. Oncology (Williston Park). 2016 Nov 15;30(11). PubMed PMID: 27854101

Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies. Oncology (Williston Park). 2016 Dec 15;30(12). PubMed PMID: 27987198

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016 Dec;35(4):547-573. PubMed PMID: 28025748

Article title: The 21-Gene Recurrence Score (RS) Assay for Node-Positive Early Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have the Clinicians Already Decided? Author(s): Jagar Jasem, MD, MPH; Christine M. Fisher, MD, MPH; Arya Amini, MD; Elena Shagisultanova, MD, PhD; Rachel Rabinovitch, MD; Virginia F. Borges, MD, MMSc; Anthony Elias, MD; and Peter Kabos, MD

Contreras-Zárate MJ, Ormond DR, Gillen AE, Hanna C, Day NL, Serkova NJ, Jacobsen BM, Edgerton SM, Thor AD, Borges VF, Lillehei KO, Graner MW, Kabos P, Cittelly DM. Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases. Front Oncol. 2017;7:252. PubMed PMID: 29164052

Banerji U, Dean E, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose HJ, Barrett JC, Carr TH, Cheung SA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates JW, Schellens JHM. A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clin Cancer Res. 2017 Oct 24. [Epub ahead of print] PubMed PMID: 29066505

Gillen AE, Brechbuhl HM, Yamamoto TM, Kline E, Pillai MM, Hesselberth JR, Kabos P. Alternative Polyadenylation of PRELID1 Regulates Mitochondrial ROS Signaling and Cancer Outcomes. Mol Cancer Res. 2017 Dec;15(12):1741-1751. PubMed PMID: 28912168

Stokes WA, Amini A, Jackson MW, Plimpton SR, Kounalakis N, Kabos P, Rabinovitch RA, Rusthoven CG, Fisher CM. Patterns of Fractionation and Boost Usage in Adjuvant External Beam Radiotherapy for Ductal Carcinoma in Situ in the United States. Clin Breast Cancer. 2017 Jun 29. [Epub ahead of print] PubMed PMID: 28797765

Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, MacLean PS, Anderson SM. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Horm Cancer. 2017 Dec;8(5-6):269-285. PubMed PMID: 28741260

Riemondy KA, Ransom M, Alderman C, Gillen AE, Fu R, Finlay-Schultz J, Kirkpatrick GD, Di Paola J, Kabos P, Sartorius CA, Hesselberth JR. Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Res. 2018 Nov 29. [Epub ahead of print] PubMed PMID: 30496484

Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III. Cancer Res. 2017 Sep 15;77(18):4934-4946. PubMed PMID: 28729413

Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018 Aug 2;20(1):82. PubMed PMID: 30071865

Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 Jul 25;3(14). [Epub ahead of print] PubMed PMID: 30046001

Stoen E, Kabos P, Borden KC, Brown RJ, Borges VF, Diamond JR. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer. Oncology (Williston Park). 2018 Jun;32(6):298-302. PubMed PMID: 29940061

Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. Front Oncol. 2017;7:94. PubMed PMID: 28555173

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers. Clin Cancer Res. 2018 May 1;24(9):2050-2059. PubMed PMID: 29066505

Stokes WA, Amini A, Jackson MW, Plimpton SR, Kounalakis N, Kabos P, Rabinovitch RA, Rusthoven CG, Fisher CM. Patterns of Fractionation and Boost Usage in Adjuvant External Beam Radiotherapy for Ductal Carcinoma in Situ in the United States. Clin Breast Cancer. 2018 Jun;18(3):220-228. PubMed PMID: 28797765

Heather Brechbuhl, Alex Barrett, Etana Kopin, Austin Gillen, Jaime Hagen, Lindsay Johnson, Jessica Finlay-Shultz, Carol A Sartorius, Kirk Hansen, Peter Kabos: Targeting the Tumor Microenvironment to Inhibit Breast Cancer Metastasis

Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?. J Natl Compr Canc Netw. 2017 Apr;15(4):494-503. PubMed PMID: 28404760

Iyer P, Jasem J, Springer MA, Klein CE, Kabos P. PALB2-Positive Breast Cancer in a 40-Year-Old Man. Oncology (Williston Park). 2017 Jan 15;31(1):50-2, 54. PubMed PMID: 28090623

Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clin Cancer Res. 2017 Apr 1;23(7):1710-1721. PubMed PMID: 27702820

Elena Shagisultanova, Michelle Borakove, Peter Kabos, Virginia Borges: Triple targeted combination therapy with tucatinib, palbociclib and fulvestrant is active in hormone receptor and HER2-positive human breast tumor cell lines.

Elias A, Kabos P. Triple negative breast cancer: A review. Internal Medicine Review. Vol 3, No 4 (2017): Vol.3 Issue 4 April 2017

Nuria Padilla Just, Jessica Finlay-Schultz, Austin E. Gillen, Diana M. Cittelly, Elizabeth A. Wellberg, Kathryn B. Horwitz, Peter Kabos and Carol A. Sartorius:Single cell RNA sequencing defines regulatory networks in ER+ breast cancer organ-specific metastases

Sara M. Tolaney, Peter Kabos, Maura N. Dickler, Luca Gianni, Valerie Jansen, Yi Lu, Suzanne Young, Hope S. Rugo: Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab

Andres Forero-Torres, Heather Han, Elizabeth Claire Dees, Robert Wesolowski, Aditya Bardia, Peter Kabos, Rachel M. Layman, Janice M. Lu, Kenneth Alan Kern, Rachelle Perea, Kristen J. Pierce, Brett Houk, Nuzhat Pathan, Hope S. Rugo: Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009).

Riemondy KA, Ransom M, Alderman C, Gillen AE, Fu R, Finlay-Schultz J, Kirkpatrick GD, Di Paola J, Kabos P, Sartorius CA, Hesselberth JR. Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Res. 2019 Feb 28;47(4):e20. PubMed PMID: 30496484

Stumpf PK, Cittelly DM, Robin TP, Carlson JA, Stuhr KA, Contreras-Zarate MJ, Lai S, Ormond DR, Rusthoven CG, Gaspar LE, Rabinovitch R, Kavanagh BD, Liu A, Diamond JR, Kabos P, Fisher CM. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. Clin Cancer Res. 2019 Jul 1;25(13):3946-3953. PubMed PMID: 30940654

Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders CK, Carrillo JA, Chalasani P, Kabos P, Puhalla SL, Tkaczuk KHR, Garcia A, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim NK. ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clin Cancer Res. 2020 Jan 22. [Epub ahead of print] PubMed PMID: 31969331

McGinn O, Ward AV, Fettig LM, Riley D, Ivie J, Paul KV, Kabos P, Finlay-Schultz J, Sartorius CA. Cytokeratin 5 alters ß-catenin dynamics in breast cancer cells. Oncogene. 2020 Jan 27. [Epub ahead of print] PubMed PMID: 31988452

Brechbuhl HM, Barrett AS, Kopin E, Hagen JC, Han AL, Gillen AE, Finlay-Schultz J, Cittelly DM, Owens P, Horwitz KB, Sartorius CA, Hansen KC, Kabos P. Fibroblast subtypes define a metastatic matrisome in breast cancer. JCI Insight. 2020 Feb 11. [Epub ahead of print] PubMed PMID: 32045383

Targeting lipid pathways in luminal breast cancer stem cells and endocrine resistance. Ashley V. Ward, Shawna B. Matthews, Etana Kopin, Peter Kabos, Michael C. Rudolph, and Carol A. Sartorius

Preclinical modeling of obesity and ER-positive breast cancer reveals a convergence of tumor intrinsic and extrinsic drivers of progression after estrogen deprivation therapy. Elizabeth A Wellberg, Peter Kabos, Britta M Jacobsen, Steven M Anderson, Carol A Sartorius, Paul S MacLean

Elena Shagisultanova, Pavani Chalasani, Ursa Brown-Glaberman, William J. Gradishar, Andrew Brenner, Alison Stopeck, Dexiang Gao, Tessa McSpadden, Peter Kabos, Virginia F. Borges (on behalf of Academic Breast Cancer Research Consortium). Tucatinib, palbociclib and letrozole in patients with HR+/HER2+ metastatic breast cancer: final analysis of phase IB safety cohort

Jennifer A. Weiss MD, Andrew Nicklawsky, Dexiang Gao, Anthony Elias MD, Virginia Borges MD, Peter Kabos MD, S. Lindsey Davis MD, Stephen Leong MD, Jennifer R. Diamond MD: Patients with Metastatic Breast Cancer Enrolled in Phase I Clinical Trials: Clinical Outcomes and Cohort Trends

Carey K. Anders, Emilie Le Rhun, Thomas Denis Bachelot, Denise A. Yardley, Ahmad Awada, Pier Franco Conte, Peter Kabos, Melissa Bear, Zhengyu Yang, Yanyun Chen, Sara M. Tolaney: A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC).

Lillian M Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Alison Schram, Andrea Varga, Andrea Wong, Helen Ambrose, Alan Barnicle, T. Hedley Carr, Elza C de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser Justin PO Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta9, Martine Roudier, Gaia Schiavon, Pedram Razavi, Udai Banerji, Sarat Chandarlapaty, José Baselga and David M Hyman: P1-19-05 - Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer

Diana M. Cittelly, Maria J. Contreras-Zarate, Ricaurte A. Marquez-Ortiz, Nicole Day, Bebhinn Nagle, Ryan Ormond, Virginia F. Borges and Peter Kabos: Estrogen-depletion therapies prevent and delay progression of brain metastasis.

Komal Jhaveri1, Eric Paul Winer2, Elgene Lim3, Jose AlejandroPerez Fidalgo4, Meritxell Bellet5, Ingrid Alina Mayer6, Valentina Boni7, Jaymin M Patel8, Aditya Bardia9, Jose Manuel Garcia10, Peter Kabos11, Mary Gates12, Ya-Chi Chen12, Jill Fredrickson12, Xiaojing Wang12, Lori Sickels Friedman12, Jill Spoerke12, Steven Gendreau12, Ciara Metcalfe12, Lichuan Liu12, Ching-Wei Chang12, Sharareh Monemi12, Monica Gonzalez12, Ursula McCurry12, Sandra Milan12, Eric William Humke12 and Sherene Loi: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer

Virginia Kaklamani1, Aditya Bardia2, Sharon Wilks3, Amy Weise4, Donald Richards5, Wael Harb6, Cynthia Osborne7, Robert Wesolowski8, Meghan Karuturi9, Paul Conkling10, Rebecca Bagley11, JungAh Jung11, Teeru Bihani11, Maureen Conlan11 and Peter Kabos: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

Teeru Bihani1, JungAh Jung1, Hitisha K Patel1, Aditya Bardia2, Peter Kabos3, Virginia Kaklamani4, Agnes Jager5, Philippe Aftimos6, Sharon Wilks7, Elisabeth de Vries8, Wael Harb9, Donald Richards10, Amy Weise11, Robert Wesolowski12, Catharina CW Menke-van der Houven van Oordt13, Paul Conkling14, Patrick Neven15 and Maureen G Conlan: Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2- advanced/metastatic breast cancer

Maller O, Drain AP, Barrett AS, Borgquist S, Ruffell B, Zakharevich I, Pham TT, Gruosso T, Kuasne H, Lakins JN, Acerbi I, Barnes JM, Nemkov T, Chauhan A, Gruenberg J, Nasir A, Bjarnadottir O, Werb Z, Kabos P, Chen YY, Hwang ES, Park M, Coussens LM, Nelson AC, Hansen KC, Weaver VM. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nat Mater. 2020 Nov 30. [Epub ahead of print] PubMed PMID: 33257795

Dwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CA. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor breast cancer. Br J Cancer. 2020 Nov 4. [Epub ahead of print] PubMed PMID: 33144693

Weiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, Diamond JR. Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. Cancer Med. 2020 Dec;9(23):8801-8808. PubMed PMID: 33063469

Brechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells. Mol Carcinog. 2020 Oct;59(10):1129-1139. PubMed PMID: 32822091

Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2020 Oct 15;26(20):5310-5319. PubMed PMID: 32694159

Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, Harrell JC, Kabos P, Sartorius CA. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res. 2020 Jun 23;22(1):68. PubMed PMID: 32576280

Brechbuhl HM, Barrett AS, Kopin E, Hagen JC, Han AL, Gillen AE, Finlay-Schultz J, Cittelly DM, Owens P, Horwitz KB, Sartorius CA, Hansen K, Kabos P. Fibroblast subtypes define a metastatic matrisome in breast cancer. JCI Insight. 2020 Feb 27;5(4). PubMed PMID: 32045383

McGinn O, Ward AV, Fettig LM, Riley D, Ivie J, Paul KV, Kabos P, Finlay-Schultz J, Sartorius CA. Cytokeratin 5 alters ß-catenin dynamics in breast cancer cells. Oncogene. 2020 Mar;39(12):2478-2492. PubMed PMID: 31988452

Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, Carrillo J, Chalasani P, Kabos P, Puhalla S, Tkaczuk K, Garcia AA, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim N. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 Jun 15;26(12):2789-2799. PubMed PMID: 31969331

Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2021 Dec 2. [Epub ahead of print] PubMed PMID: 34856027

Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VF. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Mol Cancer Ther. 2022 Jan;21(1):48-57. PubMed PMID: 34728571

Schreiber AR, Kagihara J, Eguchi M, Kabos P, Fisher CM, Meyer E, Molina E, Kondapalli L, Bradley CJ, Diamond JR. Evaluating anthracycline? ?taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study. Breast Cancer Res Treat. 2022 Jan;191(2):389-399. PubMed PMID: 34705147

Márquez-Ortiz RA, Contreras-Zárate MJ, Tesic V, Alvarez-Eraso KLF, Kwak G, Littrell Z, Costello JC, Sreekanth V, Ormond DR, Karam SD, Kabos P, Cittelly DM. IL13Ra2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases. Clin Cancer Res. 2021 Nov 15;27(22):6209-6221. PubMed PMID: 34544797

Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. NPJ Breast Cancer. 2021 Apr 16;7(1):44. PubMed PMID: 33863913

Schreiber AR, Kagihara JA, Weiss JA, Nicklawsky A, Gao D, Borges VF, Kabos P, Diamond JR. Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials. Front Oncol. 2021;11:640690. PubMed PMID: 33816286

Rugo HS, Kabos P, Beck JT, Jerusalem G, Wildiers H, Sevillano E, Paz-Ares L, Chisamore MJ, Chapman SC, Hossain AM, Chen Y, Tolaney SM. Abemaciclib in combination with pembrolizumab for HR , HER2- metastatic breast cancer: Phase 1b study. NPJ Breast Cancer. 2022 Nov 5;8(1):118. PubMed PMID: 36335120

Rao S, Han AL, Zukowski A, Kopin E, Sartorius CA, Kabos P, Ramachandran S. Transcription factor-nucleosome dynamics from plasma cfDNA identifies ER-driven states in breast cancer. Sci Adv. 2022 Aug 26;8(34):eabm4358. PubMed PMID: 36001652

Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Res Treat. 2021 Jun;187(3):883-891. PubMed PMID: 33625615

McGinn O, Riley D, Finlay-Schultz J, Paul KV, Kabos P, Sartorius CA. Cytokeratins 5 and 17 Maintain an Aggressive Epithelial State in Basal-Like Breast Cancer. Mol Cancer Res. 2022 Sep 2;20(9):1443-1455. PubMed PMID: 35639459

Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, Osborne C, Wesolowski R, Karuturi M, Conkling P, Bagley RG, Wang Y, Conlan MG, Kabos P. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol. 2021 Apr 20;39(12):1360-1370. PubMed PMID: 33513026

Sakamoto MR, Eguchi M, Azelby CM, Diamond JR, Fisher CM, Borges VF, Bradley CJ, Kabos P. New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer. J Natl Compr Canc Netw. 2021 Jan 6;19(1):29-38. PubMed PMID: 33406490

Ward AV, Matthews SB, Fettig LM, Riley D, Finlay-Schultz J, Paul KV, Jackman M, Kabos P, MacLean PS, Sartorius CA. Estrogens and Progestins Cooperatively Shift Breast Cancer Cell Metabolism. Cancers (Basel). 2022 Mar 31;14(7). PubMed PMID: 35406548

Maller O, Drain AP, Barrett AS, Borgquist S, Ruffell B, Zakharevich I, Pham TT, Gruosso T, Kuasne H, Lakins JN, Acerbi I, Barnes JM, Nemkov T, Chauhan A, Gruenberg J, Nasir A, Bjarnadottir O, Werb Z, Kabos P, Chen YY, Hwang ES, Park M, Coussens LM, Nelson AC, Hansen KC, Weaver VM. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nat Mater. 2021 Apr;20(4):548-559. PubMed PMID: 33257795

Dwyer AR, Truong TH, Kerkvliet CP, Paul KV, Kabos P, Sartorius CA, Lange CA. Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor breast cancer. Br J Cancer. 2021 Jan;124(1):217-227. PubMed PMID: 33144693

Satyanarayan Rao, Amy Han, Alexis Zukowski, Etana Kopin, Carol Sartorius, Peter Kabos, and Srinivas Ramachandran: Mapping Transcription Factor-Nucleosome Dynamics from Plasma cfDNA. BioRxiv; doi: https://doi.org/10.1101/2021.04.14.439883

Brechbuhl HM, Xie M, Kopin EG, Han AL, Vinod-Paul K, Hagen J, Edgerton S, Owens P, Sams S, Elias A, Sartorius CA, Tan AC, Kabos P. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Mol Carcinog. 2022 Mar;61(3):359-371. PubMed PMID: 34856027

Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VF. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Mol Cancer Ther. 2022 Jan;21(1):48-57. PubMed PMID: 34728571

Abstract 2611: Transcription factor-nucleosome dynamics inferred from plasma cfDNA delineates tumor and tumor-microenvironment phenotype Satyanarayan Rao, Amy Han, Alexis Zukowski, Etana Kopin, Peter Kabos and Srinivas Ramachandran Cancer Res July 1 2021 81 (13 Supplement) 2611-2611; DOI:10.1158/1538-7445.AM2021-2611

Schreiber AR, Kagihara J, Eguchi M, Kabos P, Fisher CM, Meyer E, Molina E, Kondapalli L, Bradley CJ, Diamond JR. Evaluating anthracycline? ?taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study. Breast Cancer Res Treat. 2022 Jan;191(2):389-399. PubMed PMID: 34705147

Abstract 2116: Promoter enrichment of subnucleosomes using breast cancer cell-free DNA Alexis Zukowski, Amy Han, Peter Kabos and Srinivas Ramachandran Cancer Res July 1 2021 81 (13 Supplement) 2116-2116; DOI:10.1158/1538-7445.AM2021-2116

Estradiol (E2) concentration shapes the chromatin binding landscape of the estrogen receptor:Amy L. Han, Kiran Vinod-Paul, Satyanarayan Rao, Heather M. Brechbuhl, Carol A. Sartorius, Srinivas Ramachandran, Peter Kabos

Abstract 2867: Laboratory analyses of metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide Jennifer K. Richer, Nicole S. Spoelstra, Alyse Winchester, Julia Wulfkuhle, Sharon B. Sams, Gregory Vidal, Peter Kabos, Jennifer Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Virginia Borges, Dexiang Gao, Emanuel Petricoin and Anthony D. Elias Cancer Res July 1 2021 81 (13 Supplement) 2867-2867; DOI:10.1158/1538-7445.AM2021-2867

Topiramate Decreases Radiation Cytotoxic Edema In Her2+ Brain Metastases via Aquaporin 4 inhibition. María J. Contreras-Zárate, Karen Alvarez-Eraso, Zachary Littrell, Gina Kwak, Nikki Tsuji, Peter Kabos, D. Ryan Ormond, Sana D. Karam and Diana M. Cittelly

Estrogen-depletion decreases progression of ER¯ brain metastases by promoting an anti-tumoral local immune response Maria J. Contreras-Zarate1, Karen Alvarez-Eraso1, Zachary Littrell1, Nikki Tsuji1, Sana Karam2, D. Ryan Ormond3, Peter Kabos4 and Diana M. Cittelly1

Phase II Study of Radiotherapy in Combination with Chemotherapy and Immunotherapy in Patients with PD-L1-Positive Metastatic Triple-Negative Breast Cancer. Anna R. Schreiber, Jodi Kagihara, Andrew Nicklawsky, Dexiang Gao, Anosheh Afghahi, Anthony Elias, Peter Kabos, Elena Shagisultanova, Todd Pitts, Julie Lang, Sana Karam, Virginia Borges, Christine Fisher, Jennifer R. Diamond.

Final data from AMEERA-1 Arm 2: A Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2– advanced breast cancer Mario Campone1, Sarat Chandarlapaty2, Patrick Neven3, Katarina Petrakova4, Marie Robert1, Aditya Bardia5, Peter Kabos6, Nina Masson7, Marina Celanovic8, Patrick Cohen9, Qianying Liu8, Lei Wang8, Hannah M Linden10

The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor a Christopher J Morrow1*, Larissa Carnevalli1*, Richard Baird2*, Tim Brier1, Carmella Ciardullo1, Natalie Cureton1, Mandy Lawson1, Robert McEwen1, Myria Nikolaou1, Anne C Armstrong3, Begoña Bermejo de las Heras4, Emiliano Calvo5, Eva María Ciruelos Gil6, Javier Garcia-Corbacho7, Erika Hamilton8, Jason Incorvati9, Peter Kabos10, Mafalda Oliveira11, Manish R Patel12, Manuel Ruiz-Borregó13, Nicholas Turner14, Chris Twelves15, Christos Vaklavas16, Danielle Carroll1, Steven Ching17, Nevena Cvetesic1, Michelle DuPont18, Lisa Gibbons1, Alastair Mathewson1, Rhiannon Maudsley1, Pablo Morentin Gutierrez1, Avinash Reddy18, Jaime Rodriguez Canales17, Susana Ros1, Dhivya Sudhan18, Andy Sykes1, David Whitston18, Teresa Klinowska19**, Justin P O Lindemann1**

Updated results of a Phase 1b study of gedatolisib plus palbociclib and endocrine therapy (ET) in women with HR+ advanced breast cancer (ABC): Subgroup analysis by PIK3CA mutation status. Robert Wesolowski1*, Hope Rugo2*, Erica M. Stringer-Reasor3, Hyo Han4, Jennifer M. Specht5, E. Claire Dees6, Peter Kabos7, Ingrid A. Mayer8, Ulka Vaishampayan9, Seth A. Wander 10, Janice Lu11, Keerthi Gogineni12, Alexander Spira13, Anne F. Schott14, Maysa Abu-Khalaf15, Sarah C. Mutka16, Brian F. Sullivan16, Igor Gorbatchevsky16, Rachel Layman17*

Clinical Trial of Alpelisib and Tucatinib in Patients with PIK3CA-Mutant HER2-positive Metastatic Breast Cancer. Elena Shagisultanova1, Kari Wisinski2, Chelsea Gawryletz3, Farrah Datko3, Diana Medgyesy3, Jennifer Diamond1, Virginia Borges1, Peter Kabos1

264P - AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC): S. Chandarlapaty1, H.M. Linden2, P. Neven3, K. Petrakova4, A. Bardia5, P. Kabos6, S. Braga7, V. Boni8, V. Pelekanou9, N. Ternès10, A. Gosselin10, M. Celanovic9, P. Cohen10, G. Paux9, M. Campone11

Jhaveri KL, Bellet-Ezquerra M, Turner NC, Loi S, Bardia A, Boni V, Sohn J, Neilan TG, Villanueva-Vázquez R, Kabos P, García Estévez L, Lopez-Miranda E, Perez Fidalgo JA, Perez-Garcia JM, Yu J, Fredrickson J, Moore HM, Chang CW, Bond JW, Eng-Wong J, Gates MR, Lim E. Phase Ia/b Study of Giredestrant ±Palbociclib and ±Luteinizing Hormone-releasing Hormone Agonists in Estrogen Receptor-positive, HER2-negative, Locally Advanced/Metastatic Breast Cancer. Clin Cancer Res. 2023 Nov 3. [Epub ahead of print] PubMed PMID: 37921755

Schreiber AR, O'Bryant CL, Kabos P, Diamond JR. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(10):1061-1069. PubMed PMID: 37742278

333TiP - AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer: M. Campone1, A. Bardia2, P. Kabos3, S. Chandarlapaty4, P. Neven5, V. Boni6, S. Lord7, S. Cartot-Cotton8, M. Celanovic9, A. Gosselin8, V. Pelekanou9, H.M. Linden10

Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Parris H, Gao D, McSpadden T, Mayordomo J, Diamond JR, Kabos P, Borges VF. Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR /HER2 Breast Cancer. Clin Cancer Res. 2023 Dec 15;29(24):5021-5030. PubMed PMID: 37363965

AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).:Sarat Chandarlapaty, Hannah M. Linden, Patrick Neven, Katarina Petrakova, Aditya Bardia, Peter Kabos, Sofia A. D. S. Braga, Valentina Boni, Alice Gosselin, Sylvaine Cartot-Cotton, Séverine Doroumian, Marina Celanovic, Patrick Cohen, Gautier Paux, Mario Campone

Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).: Heather M. Moore, Valentina Boni, Meritxell Bellet, Begoña Bermejo De Las Heras, Maria Gión Cortés, Catherine Oakman, Peter Schmid, Xuan Bich Trinh, Duncan Wheatley, Komal L. Jhaveri, Peter Kabos, Elgene Lim, Thierry Velu, Ciara Metcalfe, Mary R. Gates, Ching-Wei Chang, John Bond, Leonard D Goldstein, Jennifer O'Hara Lauchle, Aditya Bardia

Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Phase II trial of fulvestrant plus enzalutamide in ER /HER2- advanced breast cancer. NPJ Breast Cancer. 2023 May 20;9(1):41. PubMed PMID: 37210417

Travers SS, Fisher CM, Kabos P, Cittelly DM, Ormond DR. Breast cancer brain metastases localization and risk of hydrocephalus: a single institution experience. J Neurooncol. 2023 May;163(1):115-121. PubMed PMID: 37131107

P1-17-01. Response of persistent metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide:Jennifer Richer1, Nicole Spoelstra1, Alyse Winchester1, Julia Wulfkuhlue2, Rosa Gallagher3, Sharon Sams1, Gregory Vidal4, Peter Kabos1, Jennifer Diamond1, Elena Shagisultanova1, Anosheh Afghahi1, Jose Mayordomo1, Tessa McSpadded1, Gloria Crawford1, Virginia Borges1, Dexiang Gao1, Emanuel Petricoin1 and Anthony Elias1.

Contreras-Zárate MJ, Alvarez-Eraso KLF, Jaramillo-Gómez JA, Littrell Z, Tsuji N, Ormond DR, Karam SD, Kabos P, Cittelly DM. Short-term topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasis. Neuro Oncol. 2023 Oct 3;25(10):1802-1814. PubMed PMID: 37053041

P1-17-11. Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer: Sarat Chandarlapaty1, Hannah M Linden2, Patrick Neven3, Katarina Petrakova4, Aditya Bardia5, Peter Kabos6, Sofia Braga7, Valentina Boni8, Alice Gosselin9, Marina Celanovic10, Patrick Cohen9, Gautier Paux10, Vasiliki Pelekanou10, Nils Ternès9, Joon Sang Lee10 and Mario Campone11

Roy S, Lakritz S, Schreiber AR, Molina E, Kabos P, Wood M, Elias A, Kondapalli L, Bradley CJ, Diamond JR. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study. Eur J Cancer. 2023 May;185:69-82. PubMed PMID: 36965330

Contreras-Zárate MJ, Alvarez-Eraso KL, Jaramillo-Gómez JA, Littrell Z, Tsuji N, Ormond DR, Karam SD, Kabos P, Cittelly DM. Short-term Topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasis. bioRxiv. 2023 Feb 15. PubMed PMID: 36824740

Fibroblasts in the Obese Tumor Microenvironment Drive Early Breast Cancer Progression Ellen E. Bamberg1, Kiran Vinod-Paul1, Amy L. Han1, Elizabeth Wellberg2, Kirk Hansen3, Carol A. Sartorius4, Paul MacLean5, Peter Kabos1, Heather M. Brechbuhl1

P1-18-26. Intracranial efficacy of tucatinib, palbociclib and letrozole combination in patients with HR+/HER2+ breast cancer and brain metastases: Elena Shagisultanova1, William Gradishar2, Ursa Brown-Glaberman3, Pavani Chalasani4, Andrew Brenner5, Alison Stopeck6, Jose Mayordomo1, Jennifer Diamond1, Peter Kabos1 and Virginia F. Borges1

OT2-11-03. AMEERA-1 : Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-)PIK3CA-mutated advanced breast cancer: Mario Campone1, Aditya Bardia2, Peter Kabos3, Sarat Chandarlapaty4, Patrick Neven5, Valentina Boni6, Simon Lord7, Sylvaine Cartot-Cotton8, Marina Celanovic9, Alice Gosselin8, Vasiliki Pelekanou9 and Hannah M Linden10

OT2-11-04. Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer: Mario Campone1, Sarat Chandarlapaty2, Aditya Bardia3, Patrick Neven4, Katarina Petrakova5, Peter Kabos6, Valentina Boni7, Sofia Braga8, Marina Celanovic9, Patrick Cohen10, Alice Gosselin10, Sylvaine Cartot-Cotton10, Vasiliki Pelekanou9 and Hannah Linden11

P5-18-07. Heart rate changes, cardiac safety, and exercise tolerance from a phase Ia/b study of giredestrant (GDC-9545) ± palbociclib in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer : omas G Neilan1, Rafael Villanueva-Vázquez2, Meritxell Bellet3, Elena López-Miranda4, Laura García-Estévez5, Peter Kabos6, John Bond7, Mary R Gates7, Ching-Wei Chang7 and Valentina Boni8.

PD13-02. Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer:Rachel Layman1, Robert Wesolowski2, Hyo Han3, Jennifer M Specht4, Erica M Stringer-Reasor5, E. Claire Dees6, Peter Kabos7, Ingrid A Mayer8, Ulka Vaishampayan9, Janice Lu10, Keerthi Gogineni11, Aditya Bardia12, Anne F Schott13, Maysa Abu-Khalaf14, Doug Howkins15, Brian Sullivan15, Igor Gorbatchevsky15 and Hope Rugo16

Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy Lajos Pusztai, Ekaterina Kalashnikova, Evie Hobbs, Ursa Brown-Glaberman, Monica Mita, Paula Klein, Fengting Yan, Sima Ehsani, Wajeeha Razaq, Alison Stopeck, Manali Bhave, Michelle Loch, Sagar Sardesai, Evanthia T. Roussos Torres, Mark Burkard, Femi Okubanjo, Eric Gauthier, Angel Rodriguez, Minetta C. Liu, Peter Kabos

Professor, Medicine-Medical Oncology

Medical School

Internship

Residency

Fellowships

Languages

Department

Publications

Practice Locations

Specialty Information

School of Medicine

CU Anschutz

Fitzsimons Building